Alterity Therapeutics Ltd Stock Price, News & Analysis

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has received authorization from New Zealand's Medsafe for a Phase 2 clinical trial of its lead drug candidate ATH434, targeting Multiple System Atrophy (MSA). The trial aims to assess ATH434's impact on imaging and biomarkers over 12 months. The company reported a cash position of A$37M as of December 31, 2021, with operating cash outflows of A$4M. Additionally, a recent US patent grants exclusivity for a new class of iron chaperones, potentially beneficial for treating Parkinson's and Alzheimer's diseases.

Alterity Therapeutics (NASDAQ: ATHE) announced the granting of a new patent (No. 11,155,547) by the USPTO for compounds designed to treat neurodegenerative diseases, including Parkinson's and Alzheimer's. This composition of matter patent covers over 80 novel iron chaperone compounds, ensuring exclusivity until 2041. CEO David Stamler emphasized the significance of this patent in establishing the company as a leader in targeting iron for disease modification. The company is also seeking patent protection in other regions to strengthen its drug development and commercialization efforts.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on neurodegenerative disease treatments, announced that CEO David Stamler will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation will be available on the company's website starting January 10, 2022 at 7:00 a.m. ET.

Alterity's lead asset, ATH434, targets various Parkinsonian disorders, underpinned by a broad drug discovery platform.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has received authorization from New Zealand's Medsafe for its Phase 2 clinical trial of ATH434 in treating Multiple System Atrophy (MSA), a rare neurodegenerative disorder. The trial, set to begin in Q1 2022, will evaluate the drug's impact on α-synuclein aggregation and iron balance in the brain. ATH434 has shown promise in Phase 1 trials for safety and bioavailability. This milestone positions Alterity to potentially address the unmet needs of MSA patients, for whom there are currently no disease-modifying treatments.

Alterity Therapeutics (NASDAQ: ATHE) announced participation in two upcoming virtual investor events. CEO David Stamler will speak at the MST Financial Lifesciences & Biotech Forum on November 24, 2021, at 5:20 p.m. PST, and the Benchmark Company Discovery Conference on December 2, 2021. These events aim to highlight Alterity's innovative treatments for neurodegenerative diseases, particularly their lead asset, ATH434, targeting Parkinsonian disorders. For further details, visit www.alteritytherapeutics.com.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced its presentation at the American Autonomic Society's 32nd Annual International Symposium. The poster detailed findings from a Phase 1 trial of ATH434, a novel treatment for neurodegenerative conditions. The trial showed ATH434 was well tolerated with no cardiac adverse events and demonstrated favorable pharmacokinetics. The company plans to initiate a Phase 2 trial for Multiple System Atrophy in Q1 2022. ATH434 has received Orphan designation from the FDA and European Commission, supporting its potential in treating MSA.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the publication of two preclinical studies supporting the use of ATH434 in treating Parkinsonian disorders. The studies, published in Journal of Parkinson's Disease and Plos One, highlight ATH434's potential in alleviating gastrointestinal complications and reducing alpha-synuclein aggregation—key factors in Parkinson's disease. ATH434, well-tolerated in Phase 1 trials, has received Orphan designation for treating Multiple System Atrophy. Further research is ongoing to advance this candidate into proof-of-concept studies.

Alterity Therapeutics (NASDAQ: ATHE) announced two new preclinical studies showcasing the efficacy of ATH434 in treating Parkinsonian disorders. These studies published in the Journal of Parkinson's Disease and Plos One highlight the potential of ATH434 to alleviate gastrointestinal complications associated with Parkinson's disease by reversing colonic dysfunction and modulating iron trafficking. CEO David Stamler emphasized ATH434's promise in enhancing patient quality of life and mentioned ongoing preclinical studies aimed at advancing its clinical development.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) provided an update on its clinical programs and financials for Q1 FY22, ending September 30, 2021. The company reported a cash balance of A$41.3M and a quarterly cash outflow of A$4.9M, consistent with ongoing clinical activities. Key highlights include advancements in the ATH434 Phase 2 trial for Multiple System Atrophy (MSA) and the expansion of its bioMUSE study, which aims to refine patient selection for therapies. Intellectual property have seen significant growth, enhancing future opportunities.